Search
Rasburicase
go.drugbank.com/drugs/DB00049ApprovedInvestigationalRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified <i>Saccharomyces cerevisiae</i> strain. … The cDNA coding for rasburicase was cloned from a strain of _Aspergillus flavus_.
Products: FASTURTEC 1,5 MG/1 ML INFIZYONLUK COZELTI ICIN TOZ VE COZUCU, 1 ADET, FASTURTEC®1.5 MG / MLALTU-135
go.drugbank.com/drugs/DB05330InvestigationalALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA).
Macitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigationalMacitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH).[L35890] It was first approved by the FDA in 2013. … A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024.
Mixtures: OPSYNVI® (MACITENTAN/TADALAFILO) 10MG/40 MG TABLETAS RECUBIERTASCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingXenon Xe-129
go.drugbank.com/drugs/DB17386ApprovedInvestigationalThey undergo a process that increases nuclear polarization up to five orders of magnitude, leading to a higher MRI signal. … [Helium-3] (He-3) is the one most commonly used due to its strong signal and favorable safety profile, but its use in other applications has affected its availability.
Synonyms: Xenon, isotope of mass 129m(8.88 d)Pimecrolimus
go.drugbank.com/drugs/DB00337ApprovedInvestigationalPimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. … It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: ELIDEL CREAM 1% w/w, ELIDEL® 1% CREMAPN0621
go.drugbank.com/drugs/DB05218ExperimentalPN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis.
Mimosine
go.drugbank.com/drugs/DB01055ExperimentalMimosine is an antineoplastic alanine-substituted pyridine derivative isolated from _Leucena glauca_.
Categories: Heterocyclic Compounds, 1-RingSynonyms: (S)-2-amino-3-(3-hydroxy-4-oxo-4H-pyridin-1-yl)propanoate, (L)-MimosineUrokinase
go.drugbank.com/drugs/DB00013ApprovedInvestigationalWithdrawnUrokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. … [A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943] Urokinase was granted FDA approval on 16 January 1978.[L12138]
Products: UROKINASE KGCC INJ. 250000 IU FLAKON, 1 ADET, UROKINASE KGCC INJ. 500000 IU FLAKON, 1 ADETTelavancin
go.drugbank.com/drugs/DB06402ApprovedInvestigationalMRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others. … Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.
ATL1102
go.drugbank.com/drugs/DB04997InvestigationalATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.